Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
It may be a sign of the times at Havas when it sends out a press release trumpeting retained accounts as new-business wins. Last week, the Paris holding company told the press that Sanofi-Aventis “awarded” Euro RSCG Life “the global advertising account for the thrombosis treatment Lovenox and for Lantus and Apidra diabetes treatment.” It left out one important detail: Euro began working for Lantus in 2003 and has already rolled out the drug in 81 countries, while Lovenox and Apidra were assigned to the agency earlier this year.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in